Breaking News

PharmaForm To Manufacture Corcept Drug

Will serve as the primary commercial manufacturer for Korlym

Corcept Therapeutics has selected PharmaForm as its primary commercial manufacturer for Korlym. The FDA approved Corcept’s Korlym in February for patients with endogenous Cushing’s syndrome.

PharmaForm provides development and manufacturing services for the pharmaceutical and biotech industries. The two companies have worked together for the past several years.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters